Transrectal ultrasound (TRUS)-guided biopsy using a 12-core scheme is the standard biopsy approach for men with suspected prostate cancer. Among the benefits of TRUS-guided biopsy is its fairly good ...

Current evidence on the efficacy of transperineal template biopsy of the prostate shows an increase in diagnostic yield in patients with suspected prostate cancer who have had negative or equivocal ...

Although usually used as a confirmatory test after negative TRUS-guided biopsy, transperineal biopsy shows promise as an initial investigation Transperineal biopsy frequently requires higher levels of ...

A multicenter randomized trial compared transperineal prostate biopsy without antibiotic prophylaxis versus transrectal biopsy with targeted prophylaxis, examining infections, prostate cancer ...

You usually have this test in the outpatient department under local anaesthetic . Sometimes, you may have it in the operating theatre under a general anaesthetic. This is when you are asleep and don’t ...

Validation of an active surveillance threshold for the CCP score in conservatively managed men with localized prostate cancer.

It has been argued that evaluation for suitability of focal ablation is derived from template transperineal prostate mapping biopsies using a 5 mm sampling frame. [40,41,42] This technique has ...

Please provide your email address to receive an email when new articles are posted on . Transperineal prostate cancer biopsies did not cause any infections in a randomized trial. U.S. and European ...

Although MRI detects radiorecurrent cancer overall, it may not accurately locate all lesions in the prostate gland. When prostate cancer recurrence after radiation therapy is suspected, clinicians ...

The transperineal template biopsy (TPB) uses a biplanar ultrasound transducer mounted on a stand with a brachytherapy template grid. This helps to take multiple cores from all areas of the prostate in ...

About two million American men undergo transrectal biopsies each year to diagnose prostate cancer or to monitor low-risk and favorable intermediate-risk prostate cancers for active surveillance (AS).